1. Home
  2. AREB vs SILO Comparison

AREB vs SILO Comparison

Compare AREB & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AREB

American Rebel Holdings Inc.

HOLD

Current Price

$0.51

Market Cap

5.5M

Sector

Industrials

ML Signal

HOLD

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$0.38

Market Cap

4.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AREB
SILO
Founded
2014
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Plastic Products
Apparel
Sector
Industrials
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.5M
4.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
AREB
SILO
Price
$0.51
$0.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
614.1K
168.2K
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,014,691.00
$72,102.00
Revenue This Year
N/A
$1.86
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$0.33
52 Week High
$1,205.00
$2.09

Technical Indicators

Market Signals
Indicator
AREB
SILO
Relative Strength Index (RSI) 32.16 45.06
Support Level $0.44 $0.37
Resistance Level $0.84 $0.40
Average True Range (ATR) 0.09 0.02
MACD 0.00 0.01
Stochastic Oscillator 19.93 55.44

Price Performance

Historical Comparison
AREB
SILO

About AREB American Rebel Holdings Inc.

American Rebel Holdings Inc develops self-defense, safe storage, and patriotic product areas using a wholesale distribution network, utilizing personal appearances, musical venue performances, as well as e-commerce and television. It designs, manufactures, and markets concealed carry products. It offers products ranging in Backpacks, jackets, coats, and Others. The Company views its operations and manages its business as one operating segment engaged in patriotic goods, comprised of safes, soft goods, and beer.

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

Share on Social Networks: